Metastatic pancreatic cancer with activating BRAF V600E mutations:A case report  

作　　者：Fang Li Feng Shen 

机构地区：[1]Department of Medical Oncology,Zhongshan Hospital(Xiamen),Fudan University,Xiamen 361015,Fujian Province,China [2]Xiamen Clinical Research Center for Cancer,Xiamen 361015,Fujian Province,China [3]Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province,Xiamen 361015,Fujian Province,China

出　　处：《World Journal of Clinical Cases》2025年第16期52-59,共8页世界临床病例杂志(英文)

基　　金：Supported by Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province.

摘　　要：BACKGROUND Pancreatic cancer(PC)is a highly malignant tumor that is resistant to chemotherapy,radiotherapy and immunotherapy.Combination chemotherapy regimens are the standard first-line regimens for metastatic disease,with a median survival<12 months.Although recurrent genomic alterations such as the BRAF V600E mutation have been reported in PC,evidence supporting the clinical effectiveness of molecularly guided targeted therapies is limited.CASE SUMMARY We report a case of a 33-year-old male who was referred to our department with weight loss of 5 kg in 2 months,anorexia and abdominal pain.Imaging showed extensive lesions involving the pancreas,liver,bones,muscles and lymph nodes accompanied by elevated carbohydrate antigen 19-9(CA19-9)and carcinoembryonic antigen(CEA).Biopsy yielded a diagnosis of PC.Treatment with gemcitabine and nab-paclitaxel was initiated,but the disease progressed in<2 months even though the patient’s general condition improved.Molecular testing revealed the presence of BRAF mutation.Dabrafenib/trametinib combination therapy was introduced,and the patient was treated for 2 months with a decrease in CA19-9 and CEA levels,but he died after 2 months of treatment.CONCLUSION BRAF alterations are infrequent in PC.This case highlights the significance of molecular profiling in patients with PC,especially in patients with a high tumor burden.

关 键 词：Pancreatic cancer BRAF gene mutation Targeted therapy Prognosis Case report 

分 类 号：R735.9[医药卫生—肿瘤]